| Similar Articles |
|---|
 |
Bio-IT World
June 17, 2004
Michael A. Greeley |
A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools.   |
Bio-IT World
March 8, 2005
Patricia Reilly |
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending. |
Bio-IT World
Dec 2005/Jan 2006
Michael A. Greeley |
Infinite Demand for the Unavailable The bio-IT field is once again attracting venture capital, but at a more moderate, deliberate pace than the euphoria of the late 1990s. |
Bio-IT World
March 2006
Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. |
Bio-IT World
July 2005
Michael A. Greeley |
CEO Lessons on Product and Market In the face of extraordinary R&D budgets generated by biopharma industries, bio-IT companies must refine their value propositions in the hopes that meaningful (predictable and repeatable) revenue streams can be created. |
Bio-IT World
October 14, 2004
Michael Greeley |
Go East Business is great in China, and the government is strongly encouraging the local biotech industry. |
Bio-IT World
July 15, 2003
Michael Greeley |
Finally, the Bottom Has pharma bought all the solutions it needs? The flood of genomic data indicates no. |
Bio-IT World
April 2007
Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? |
Bio-IT World
March 10, 2003
Michael Greeley |
Too Much Informatics Did bioinformatics companies forget about the fundamental law of supply and demand? |
Bio-IT World
January 13, 2003
Michael Greeley |
What Do We Do Now? Like it or not, the supply of capital is an important ingredient in the continued development of the bio-IT industry. Appreciating and understanding the forces currently at work in the VC marketplace can only help in raising capital. |
Bio-IT World
April 16, 2004 |
Portraits in Proteomics Advances in identifying protein biomarkers are spurring new hope in cancer diagnostics, expediting detection and easing testing. |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Bio-IT World
July 2005
Robert M. Frederickson |
Amassing Mass Spectrometry Tools Mass spectrometry is a key tool in the effort to identify protein biomarkers of human disease. Manufacturers have met major challenges in adapting this technology to protein discovery, both qualitatively and quantitatively. |
Bio-IT World
June 2005
Michael A. Greeley |
Who Wants to Be a VC? The objective is to stay relevant to a venture firm while the industry contracts. Develop the case that you can help create great companies (and great returns) because you have built a Rolodex and an ability to identify patterns of success. |
Bio-IT World
August 13, 2002
Malorye Branca |
The Proteomics Odyssey Efforts to map the constellation of protein interactions in humans gather momentum as companies vie to provide tools to capitalize on the potential of proteomics. But can proteomics prevail where some feel genomics has failed? |
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? |
Bio-IT World
July 14, 2004
Julia Boguslavsky |
Mass Spec Show and Tell The conference director for Cambridge Healthtech Institute offers highlights from the annual meeting of the American Society for Mass Spectrometry, particularly on mass spec and proteomics. |
Bio-IT World
November 2005
Charles Firneno |
The Information Value Chain By looking at the evolution of pharma's information networks, strategies can be designed for IT solutions such as CRM, CTMS, AERSs, and business analytics software to deliver the highest possible value. |
Bio-IT World
June 2006
Michael A. Greeley |
Backwards Influence Biotech companies must think downstream as they consider what drugs to develop. Many companies are introducing cost-effectiveness analysis earlier in the discovery process. |
Bio-IT World
April 15, 2003
Michael Greeley |
Bio Battles Upstream As biotech business models evolve, the question remains: Which will survive? |
Bio-IT World
August 15, 2005
Robert M. Frederickson |
What's 'Post' About Postgenomic? Bioinformatics tools can help organize and study genomic sequences that were discovered in the '90s. The tools help with tasks like analyzing gene expression, predicting protein structure and function, and establishing networks of interacting protein in cells. |
Bio-IT World
April 2006
Michael A. Greeley |
The Good, The Bad, and The Ugly VCs will not support a sector where consistent compelling exits are not evident. Unfortunately, the bio-IT field still suffers from this. |
Bio-IT World
September 2005
Michael A. Greeley |
Harvesting Patient Data Longitudinal data tools will allow pharmaceuticals to optimize sales force deployments and distribution strategies based on medical impacts of their compounds across various population sets. |
Bio-IT World
May 9, 2003
Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development. |
Bio-IT World
October 9, 2002
Debra Goldfarb |
A Study in Contrasts Recently, IDC conducted a pair of focus groups as part of a broader study on technology adoption across bio-IT workloads. |
Bio-IT World
April 16, 2004
Robert Frederickson |
Trial Separations Protein separation through the digital ProteomeChip microchip takes merely minutes, resulting in significantly increased productivity. |
Pharmaceutical Executive
January 1, 2012
Bill Drummy |
Scared to Death The pharma industry's risk-aversion is risking its survival. Where did the courage to innovate go? |
AskMen.com
Dave Golokhov |
Best Workout Protein Foods We've compiled a list of 30 quality protein sources that you can add to your diet if you're working out frequently. |
Pharmaceutical Executive
April 10, 2014
Christini & Kaitin |
Regional Trends in Bioinnovation Investment Can the Cambridge model be duplicated? |
Entrepreneur
May 2005
John F. Ince |
Back in Black The Venture Capital industry is fattening up again -- but what does this mean for the entrepreneur? For the short term anyway, an increase in the supply of available capital. |
Bio-IT World
September 16, 2004
Michael A. Greeley |
Platforms for Pathways Investor interest in the next great blockbuster drug has been blistering hot; Phase II and Phase III compound companies are being funded at a near record-breaking pace now that the IPO window seems to be slightly open |
